Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | MIF | P14174 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32686865 | 0.88 | ALDH1A1 (0.35) | NPC1TNIKHPGDCYP1A2CYP3A4 | |
| SCHEMBL32686785 | 0.88 | MIF (0.35) | NPC1TNIKHPGDCYP1A2CYP3A4 | |
| SCHEMBL32686821 | 0.87 | NPC1 (0.46) | NPC1TNIKHPGDCYP1A2CYP3A4 | |
| SCHEMBL32686755 | 0.87 | NPC1 (0.34) | NPC1TNIKHPGDCYP1A2CYP3A4 | |
| SCHEMBL32686912 | 0.87 | TNIK (0.36) | NPC1TNIKHPGDCYP1A2CYP3A4 | |
| SCHEMBL32686803 | 0.86 | SIGMAR1 (0.35) | NPC1TNIKHPGDCYP1A2CYP3A4 | |
| SCHEMBL32686854 | 0.86 | TNIK (0.33) | NPC1TNIKHPGDCYP1A2CYP3A4 | |
| SCHEMBL32686757 | 0.86 | TP53 (0.44) | NPC1CYP1A2CYP3A4CYP2C9KMT2A | |
| SCHEMBL32686881 | 0.85 | NPC1 (0.33) | NPC1TNIKHPGDCYP1A2CYP3A4 | |
| SCHEMBL32686836 | 0.85 | TNIK (0.34) | NPC1TNIKMIFTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | NPC1 200/4885TNIK 4286/4885HPGD 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.